| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 updated data readout example | IGC-AD1 Agitation in Alzheimer's dementia (symptomatic treatment); planned disease‑modifying investigations | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | |
Phase 2 updated data readout example | IGC-AD1 Agitation in Alzheimer's dementia (symptomatic treatment); planned disease‑modifying investigations | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | |
Phase 2 updated data readout example | IGC-AD1 Agitation in Alzheimer's dementia (symptomatic treatment); planned disease‑modifying investigations | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
IGC Pharma, Inc.$0.26
0 (-1.19%)
D 24Pipeline Score Richly Valued Biotech · Clinical
Market Cap
28.83 M
EPS
-
P/E Ratio
-
Value Trade
480.87 K
SEC Financials
Q1 2026Dilution Risk
Revenue
317.00 K
R&D Expenses
1.27 M
Operating CF
-1.22 M
Total Assets
9.19 M
Total Liabilities
3.06 M
Equity
6.12 M
D/E Ratio
12,345
-2.07 %
Week
-8.16 %
1 Month
14.74 %
3 Month
-8.16 %
6 Month
-79.43 %
5 Year
-99.47 %
All Time
Cash Data
Cash Position
235.00 K
Monthly Burn
408.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
204.34 K
52 Week Range
0.24 - 0.50
% held by Insiders
27.08 %
% held by Institutions
4.25 %
Enterprise Value
29.52 M
Total Shares
98.84 M
Short %
0.66 %
Float Shares
73.53 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for IGC Pharma, Inc.
47Total events
1Upcoming
11Tier-1 (high impact)
2006 – 2026Coverage
Upcoming catalysts 1
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
▲Enrollment CompleteIGC-AD1Trial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D24
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 23%
Micro Cap (rank 703 of 912)
Percentile RankIGC Pharma, Inc. faces pipeline headwinds (24/100), with $255M risk-adjusted pipeline value, led by IGC-AD1-Active in Alzheimer Disease (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGC-AD1-Active Small molecule | Alzheimer Disease | Phase 2 | NCT05543681 | 11% | $193M | RECRUITING | 164 | AVERAGE | B (66) | Aug 1, 2026 | MODERATE_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IGC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IGC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IGCIGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
IGC Pharma will present its AI portfolio at AAIC 2026, focusing on advancements in Alzheimer's research. The AHA platform, a key feature, reduces data harmonization time by 90%. The company aims to enhance patient identification and clinical workflows through machine learning. Additionally, IGC-AD1 is currently in Phase 2 trials for Alzheimer's-related agitation.
Read more →IGCIGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
IGC Pharma's CEO Ram Mukunda and CFO Claudia Grimaldi purchased over 4.27 million shares of common stock for $1.15 million, converting outstanding debts into equity. This transaction reflects their commitment to the company's Alzheimer's therapeutic program and aligns their interests with shareholders. The shares were issued in a private placement and approved by independent directors.
Read more →IGCIGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
IGC Pharma has announced the beta launch of its Agentic Harmonization Assistant (AHA), which reduces the time needed for harmonizing Alzheimer's datasets by 90%. The platform aims to facilitate the conversion of fragmented biomedical data into interoperable formats. AHA will be showcased at the upcoming Alzheimer’s Association International Conference 2026, highlighting its potential for rapid cohort generation and cross-study analysis. Additionally, IGC's lead therapeutic asset, IGC-AD1, is currently in Phase 2 trials for Alzheimer’s dementia.
Read more →IGCPsilocybin and Mental Health
Psilocybin, the active compound in magic mushrooms, is gaining attention for its potential mental health benefits, particularly in treating refractory depression and anxiety. Studies indicate that macro-doses can lead to significant improvements in mood and cognition, with effects lasting several months. However, safety concerns and the need for further research remain critical.
Read more →IGCIGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
IGC Pharma has announced that its Phase 2 CALMA trial for IGC-AD1 has successfully enrolled 146 patients, meeting its target. The trial aims to evaluate the treatment for agitation associated with Alzheimer's dementia. The company is now focused on generating quality data for a comprehensive topline analysis as it moves into the final phase of the trial.
Read more →IGCAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
IGC Pharma, a clinical-stage biotechnology company, has received an updated price target of $5.50 from Ascendiant Capital Markets. This increase is attributed to the company's clinical advancements, particularly in the Phase 2 CALMA trial for Alzheimer's disease. The report suggests that further clinical data and developments in 2026 could act as catalysts for the company's stock performance.
Read more →IGCIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
IGC Pharma has added the Icahn School of Medicine at Mount Sinai as a clinical site for its Phase 2 CALMA trial, which evaluates IGC-AD1 for agitation in Alzheimer's disease. This addition is part of the company's strategy to enhance site quality and patient access as the trial nears completion. With 80% of participants already enrolled, IGC Pharma aims to maintain rigorous standards for data integrity and execution.
Read more →IGCIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
IGC Pharma reported its first quarter 2026 financial results, highlighting significant progress in the CALMA Phase 2 trial for IGC-AD1, with 80% patient enrollment achieved. The company expanded its clinical site network and strengthened its AI capabilities. However, it also reported an increased net loss and rising R&D expenses, emphasizing the inherent risks in clinical trials.
Read more →IGCIGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
IGC Pharma has added Kerwin Medical Center in Dallas to its Phase 2 CALMA trial for IGC-AD1, targeting agitation in Alzheimer's disease. With approximately 80% enrollment already achieved, this addition aims to enhance patient access and recruitment. The center's Principal Investigator, Dr. Alka Khera, brings valuable expertise in behavioral neurology, supporting the trial's operational rigor as it nears completion.
Read more →IGCPharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
IGC Pharma, Inc. has announced a strategic 12-part media partnership with New to The Street to boost its visibility among investors. The collaboration will utilize long-form televised interviews and digital amplification to reach a combined audience of over 4.45 million. IGC Pharma is focused on developing therapeutics for Alzheimer's disease, including its lead asset, IGC-AD1, which is currently in Phase 2 trials. Despite the positive outlook of the partnership, the company faces risks related to commercialization and regulatory approvals.
Read more →IGCIGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
IGC Pharma has received a Notice of Allowance from the Canadian Intellectual Property Office for its proprietary composition related to IGC-AD1, a treatment for agitation in Alzheimer's disease. This patent protection enhances the commercial viability of IGC-AD1 as the Phase 2 CALMA trial nears enrollment completion, with 70% of participants already enrolled. CEO Ram Mukunda emphasized the importance of this protection for the drug's strategic development.
Read more →IGCIGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation
IGC Pharma has achieved approximately 70% enrollment in its Phase 2 CALMA trial for IGC-AD1, aimed at treating agitation in Alzheimer's patients. The company operates 23 active sites across 26 locations and anticipates completing enrollment by mid-2026. This milestone is seen as a significant reduction in operational risks, paving the way for further progress towards trial results.
Read more →IGC▲ +6%on this news
IGC Pharma Announces Results of 2025 Annual
IGC Pharma, a clinical-stage biotechnology company, announced the results of its 2025 Annual Meeting of Stockholders held on October 10, 2025. All proposals, including the election of board members and the ratification of an accounting firm, were passed. The company is focused on developing innovative treatments for Alzheimer's disease using AI, including the cannabinoid-based therapy IGC-AD1 currently in Phase 2 trials. Notably, the meeting approved a significant increase in the number of authorized shares and a grant of stock to incentivize employees.
Read more →IGCDate: June 16, 2025 NYSEAmerican: IGC 1 NYSE AMERICAN: IGC - Service to humanity -
IGC Pharma, Inc. (IGC) has showcased its drug candidate IGC - AD1, which targets Alzheimer's disease through dual-agent liquid therapy. This product has passed rigorous preclinical evaluations, confirming its safety and efficacy in reducing amyloid levels. Moreover, IGC - AD1 is now approved for clinical investigation, based on its ability to stabilize neurotransmitter imbalances and address key symptoms of the disease. The company emphasizes that its forward-looking statements regarding the drug's prospects are subject to various risks and uncertainties.
Read more →IGCIGC Announces Rebranding, Changes Name to IGC Pharma, Inc.
India Globalization Capital, Inc. will rebrand itself as IGC Pharma, Inc. on March 30, 2023, to better reflect its focus on drug development, particularly for Alzheimer's disease. The company highlights IGC-AD1, a THC-based compound currently undergoing Phase 2 trials for agitation related to Alzheimer's. This change signifies a strategic shift to emphasize its role in developing cannabinoid-based therapies and its consumer wellness brand, Holief™, which addresses several women's health issues. CEO Ram Mukunda expressed optimism about the company's progress and market traction.
Read more →IGCIGC Announces Updated Life Sciences Presentation
IGC Announces Updated Life Sciences Presentation POTOMAC, Md., Dec. 20, 2022 -- India Globalization Capital, Inc. (NYSE American: IGC) ("IGC" or the "Company"), today announces that a life sciences presentation has been filed with the SEC on Form 8K and is available at https://w
Read more →IGCIGC Announces Adjournment of Annual Meeting Voting for Proposal Four to
IGC Announces Adjournment of Annual Meeting Voting for Proposal Four to February 28, 2018 Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of October 5, 2017 Bethesda, January 2, 2018 (GLOBENEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC), adj
Read more →IGCIGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to
IGC Announces Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 29, 2017 Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of October 5, 2017 Bethesda, December 18, 2017 (GLOBENEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: I
Read more →IGCIGC Announces Results of Annual Shareholders Meeting Bethesda
IGC Announces Results of Annual Shareholders Meeting Bethesda, November 13, 2017 (GLOBENEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC), announced that during its 2016-2017 Annual Meeting of Shareholders scheduled for, and convened on November 8, 2017, voting
Read more →IGCNYSE American Extends India Globalization Capital Compliance Plan Period BETHESDA, MD--(GlobeNewsWire
NYSE American Extends India Globalization Capital Compliance Plan Period BETHESDA, MD--(GlobeNewsWire - October 12, 2017) - India Globalization Capital Inc. (NYSE American: IGC) announces that on October 11, 2017 it received notice from NYSE American LLC ("the Exchange") that it
Read more →IGCIGC Acquires Exclusive Rights to THC-based treatment for Alzheimer's Disease Bethesda
IGC Acquires Exclusive Rights to THC-based treatment for Alzheimer's Disease Bethesda, June 12, 2017 - India Globalization Capital, Inc. (NYSE-MKT: IGC) is pleased to announce that it has entered into a definitive license agreement with the University of South Florida making IGC
Read more →IGCThe IGC Executive Summary, dated
The IGC Executive Summary, dated May 25, 2017 can be viewed in PDF format by clicking here: ex99-1.pdf A Leader in Cannabis-Based Combination Therapies Develop, patent, test, and commercialize cannabis-based pharmaceutical, nutraceutical, and veterinary medicines. Cannabis mol
Read more →IGCIndia Globalization Capital, Inc. (IGC) Engages NetworkNewsWire for Corporate Communications Solutions
India Globalization Capital, Inc. (IGC) Engages NetworkNewsWire for Corporate Communications Solutions NEW YORK - April 25, 2017 - India Globalization Capital, Inc. ("the Company") (NYSE MKT: IGC), engaged in the development of cannabis-based combination therapies to treat a var
Read more →IGCNYSE MKT Extends India Globalization Capital Compliance Plan Period BETHESDA, MD--(GlobeNewsWire
NYSE MKT Extends India Globalization Capital Compliance Plan Period BETHESDA, MD--(GlobeNewsWire - April 21, 2017) - India Globalization Capital Inc. (NYSE MKT: IGC) announces that on April 20, 2017 it received notice from NYSE MKT LLC ("the Exchange") that it has accepted the C
Read more →IGCIndia Globalization Capital Receives Letter from NYSE MKT LLC BETHESDA, MD--(GlobeNewsWire
India Globalization Capital Receives Letter from NYSE MKT LLC BETHESDA, MD--(GlobeNewsWire - April 4, 2017) - India Globalization Capital Inc. (NYSE MKT: IGC) announces that on April 3, 2017, it received a NYSE MKT LLC notice indicating that the Company has fallen below certain
Read more →IGCIndia Globalization Capital Announces the Extension of Warrants' Expiry Date and Inducement Grant to its CFO BETHESDA, MD--(GlobeNewsWire
India Globalization Capital Announces the Extension of Warrants' Expiry Date and Inducement Grant to its CFO BETHESDA, MD--(GlobeNewsWire - February 17, 2017) - India Globalization Capital Inc. (NYSE MKT: IGC) announces the extension of the expiration date for 11,656,668 outsta
Read more →IGCIGC Appoints John Cherin as CFO, Treasurer and PAO Bethesda
IGC Appoints John Cherin as CFO, Treasurer and PAO Bethesda, November 21, 2016 - India Globalization Capital, Inc. (NYSE-MKT:IGC) announces that on November 15, 2016 it appointed Mr. John (Giovanni) Cherin to the position of CFO, Treasurer and Principal Accounting Officer (PAO).
Read more →IGCIGC Acquires 10% Stake in 1,000-Room Luxury Hotel Development Project in Genting Highlands, Malaysia BETHESDA, Md.
IGC Acquires 10% Stake in 1,000-Room Luxury Hotel Development Project in Genting Highlands, Malaysia BETHESDA, Md., August 4, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT: IGC) announces that it has acquired a 10% stake in a 1,000-room luxury hotel develo
Read more →IGCIGC Invests in Farming Facility Accelerating Initiative for the Legal Cannabis Farming Marketplace Bethesda
IGC Invests in Farming Facility Accelerating Initiative for the Legal Cannabis Farming Marketplace Bethesda, April 6, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (IGC) announces today that it has acquired 51% of M10-Plantation, a company located in Malaysia with e
Read more →IGCissued on
Press release issued on March 29, 2016 India Globalization Capital Raises $300 Thousand in Direct Equity Investment Bethesda, March 29, 2016 (GLOBE NEWSWIRE) - India Globalization Capital, Inc. (NYSE MKT: IGC), announced that it has raised $300,000 in a private placement. 681,8
Read more →IGCIGC Completes Satisfactory Settlement with Sricon Exchanges Minority Interest for 5 Acres of Prime Land in India Bethesda
IGC Completes Satisfactory Settlement with Sricon Exchanges Minority Interest for 5 Acres of Prime Land in India Bethesda, March 8, 2016 (GLOBENEWSWIRE) - India Globalization Capital, Inc. (NYSE MKT: IGC) announced that it has completed the settlement with Sricon exchanging its
Read more →IGCIndia Globalization Capital $50 Strike Warrants to be Removed from NYSE MKT Bethesda
India Globalization Capital $50 Strike Warrants to be Removed from NYSE MKT Bethesda, Feb. 29, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT: IGC), announced today that the staff of NYSE Regulation has determined to delist its warrants (expiring March 6, 2
Read more →IGCIGC Expands Infrastructure Development Capabilities with Acquisition Accelerates Initiatives & Suite of Service Offerings for the Legal Cannabis Farming Marketplace Bethesda
IGC Expands Infrastructure Development Capabilities with Acquisition Accelerates Initiatives & Suite of Service Offerings for the Legal Cannabis Farming Marketplace Bethesda, February 16, 2016 (GLOBENEWSWIRE) -- India Globalization Capital, Inc. (IGC) announces today that it ha
Read more →IGCIGC Announces Phytocannabinoid Focused Pharmaceutical Unit
Bethesda, MD, June 10, 2015 (GLOBE NEWSWIRE) -- IGC, Inc. (NYSE-MKT: IGC) announces the third vertical in its effort to gain a leading position in the emerging legal cannabis industry. Our strategy is to develop a product portfolio of phytocannabinoid-based therapies for the t
Read more →IGCIGC, Inc. Announces Third Quarter Financial Results BETHESDA, MD--(Globe Newswire
IGC, Inc. Announces Third Quarter Financial Results BETHESDA, MD--(Globe Newswire - February 13, 2015 - India Globalization Capital, Inc. (NYSE MKT: IGC) announced financial results for the third quarter ended December 31, 2014, ("fiscal Q3 2015"); for the fiscal year that ends
Read more →IGCIGC expands legal cannabis strategy through the acquisition of Midtown Partners Will create crowdfunding site for legal cannabis industry Will focus on equity research for legal cannabis industry Will focus on investment
IGC expands legal cannabis strategy through the acquisition of Midtown Partners Will create crowdfunding site for legal cannabis industry Will focus on equity research for legal cannabis industry Will focus on investment banking services for legal cannabis industry Bethesda,
Read more →IGCIGC Announces Adjournment of Annual Meeting; Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of
IGC Announces Adjournment of Annual Meeting; Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of July 15, 2014 Bethesda, August 27, 2014 (GLOBAL NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT: IGC), announced that its 2014 Annual Meeting of Stockholders
Read more →IGCIndia Globalization Capital Executes Off Take Agreement to Support Production Growth of High-Grade Iron Ore Company to Utilize Existing Beneficiation Plant Bethesda, MD
India Globalization Capital Executes Off Take Agreement to Support Production Growth of High-Grade Iron Ore Company to Utilize Existing Beneficiation Plant Bethesda, MD, January 30, 2014 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT: IGC), a company competing
Read more →IGCIGC Partners with TerraSphere to Develop Multiple Vertical Farming Sites Furthers Technology and Production Capacity in Preparation for Legal Cannabis Bethesda
IGC Partners with TerraSphere to Develop Multiple Vertical Farming Sites Furthers Technology and Production Capacity in Preparation for Legal Cannabis Bethesda, July 3, 2014 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT: IGC) announced that it has entered into
Read more →IGCIGC Completes Acquisition of HK-Based Trading Company Bethesda
IGC Completes Acquisition of HK-Based Trading Company Bethesda, June 4, 2014 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT: IGC), announced that it has completed its proposed acquisition of Golden Gate, a Hong Kong based trading company. As previously reported,
Read more →IGCIndia Globalization Capital Raises about $506 Thousand in Registered Direct Offering Bethesda
India Globalization Capital Raises about $506 Thousand in Registered Direct Offering Bethesda, April 2, 2014 (GLOBE NEWSWIRE) - India Globalization Capital, Inc. (NYSE MKT: IGC), announced today that it has received commitments from investors to purchase $506,250 of its Common
Read more →IGCIndia Globalization Capital Provides Update on Acquisition and Diversification Strategy Bethesda
India Globalization Capital Provides Update on Acquisition and Diversification Strategy Bethesda, March 11, 2014 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT: IGC), announced that it has commenced a comprehensive review of potential acquisition candidates as p
Read more →IGCSOURCE: India Globalization Capital, Inc. India Globalization Capital Announces Reverse Stock Split to Regain Compliance with the NYSE MKT BETHESDA, MD--(Globe Newswire
SOURCE: India Globalization Capital, Inc. India Globalization Capital Announces Reverse Stock Split to Regain Compliance with the NYSE MKT BETHESDA, MD--(Globe Newswire - April 12, 2013) - India Globalization Capital, Inc. (NYSE MKT: IGC), a company competing in the rapidly gro
Read more →IGCSOURCE: India Globalization Capital, Inc.
SOURCE: India Globalization Capital, Inc. India Globalization Capital Announces the Delisting of its Units from NYSE MKT BETHESDA, MD--(GlobeNewswire - February 6, 2013) - India Globalization Capital, Inc. (NYSE MKT: IGC) (NYSE Amex: IGC), a company competing in the rapidly gro
Read more →IGCIndia Globalization Capital Announces a Change in its Board of Directors BETHESDA, MD--(Marketwire
India Globalization Capital Announces a Change in its Board of Directors BETHESDA, MD--(Marketwire -December 27, 2012) - India Globalization Capital, Inc. (NYSE MKT: IGC), a company competing in the rapidly growing materials and infrastructure industry in India, announced today
Read more →IGCIndia Globalization Capital Announces a Change in its Board of Directors and the Creation of a Board of Advisors for China BETHESDA, MD--(Marketwire
India Globalization Capital Announces a Change in its Board of Directors and the Creation of a Board of Advisors for China BETHESDA, MD--(Marketwire - June 1, 2012) - India Globalization Capital, Inc. (NYSE MKT: IGC) (NYSE Amex: IGC), a company competing in the rapidly growing
Read more →IGCINDIA GLOBALIZATION CAPITAL ENTERS INTO A PARTNERSHIP TO PROVIDE IRON ORE TO CHINESE STEEL MILLS BETHESDA, MD -(Marketwire
INDIA GLOBALIZATION CAPITAL ENTERS INTO A PARTNERSHIP TO PROVIDE IRON ORE TO CHINESE STEEL MILLS BETHESDA, MD -(Marketwire - August 9, 2011) - India Globalization Capital, Inc. (NYSE Amex: IGC), a company competing in the rapidly growing materials and infrastructure industry in
Read more →IGCIndia Globalization Capital Announces Financial Results for End of Fiscal Year 2011 BETHESDA, MD--(Marketwire
India Globalization Capital Announces Financial Results for End of Fiscal Year 2011 BETHESDA, MD--(Marketwire July 14, 2011) - India Globalization Capital, Inc. (NYSE Amex: IGC), a company competing in the rapidly growing materials and infrastructure industry in India, announced
Read more →IGCIndia Globalization Capital Announces a change in its Board of Directors BETHESDA, MD--(Marketwire
India Globalization Capital Announces a change in its Board of Directors BETHESDA, MD--(Marketwire - March 11, 2011) - India Globalization Capital, Inc. (NYSE Amex: IGC), a company competing in the rapidly growing materials and infrastructure industry in India, announced today t
Read more →IGCIndia Globalization Capital Announces Fiscal Third Quarter Results BETHESDA, MD--(Marketwire
India Globalization Capital Announces Fiscal Third Quarter Results BETHESDA, MD--(Marketwire - February 23, 2011) - India Globalization Capital, Inc. (NYSE Amex: IGC) announced financial results for its third fiscal quarter ended December 31, 2010. IGC competes in the rapidly gr
Read more →IGCIndia Globalization Capital Files Amended 10-K for Fiscal Year Ended
India Globalization Capital Files Amended 10-K for Fiscal Year Ended March 31, 2010 with an unqualified opinion regarding its prior deconsolidation transaction and issues market guidance concerning the status of its SEC registration statements BETHESDA, MD--(Marketwire - Februa
Read more →IGCINDIA GLOBALIZATION CAPITAL PROVIDES UPDATE ON ITS IRON ORE BUSINESS BETHESDA, MD -(Marketwire
INDIA GLOBALIZATION CAPITAL PROVIDES UPDATE ON ITS IRON ORE BUSINESS BETHESDA, MD -(Marketwire - December 3, 2010) - India Globalization Capital, Inc. (NYSE Amex: IGC), a company competing in the rapidly growing materials and infrastructure industry in India, provides an update
Read more →IGCIndia Globalization Capital Announces $35 Million Iron Ore Supply Contract with Chinese Mining & Smelting Group Customer Renewal Option Could Bring Additional $176 Million Brings Iron Ore Backlog to $200 Million over 5 Y
India Globalization Capital Announces $35 Million Iron Ore Supply Contract with Chinese Mining & Smelting Group Customer Renewal Option Could Bring Additional $176 Million Brings Iron Ore Backlog to $200 Million over 5 Year Period BETHESDA, Md., May 27, 2010- India Globalizati
Read more →IGCIndia Globalization Capital Plan Receives NYSE AMEX Acceptance BETHESDA, Md.
India Globalization Capital Plan Receives NYSE AMEX Acceptance BETHESDA, Md., May 4, 2010 - MARKETWIRE - India Globalization Capital, Inc. (NYSE Amex: IGC), a company competing in the rapidly growing materials and infrastructure industry in India, today announced that its plan s
Read more →IGCIndia Globalization Capital Announces $160 Million, 5 Year Iron Ore Supply Contract with Leading Chinese Steel Manufacturer BETHESDA, Md.
India Globalization Capital Announces $160 Million, 5 Year Iron Ore Supply Contract with Leading Chinese Steel Manufacturer BETHESDA, Md., April 27, 2010- India Globalization Capital, Inc. (NYSE Amex: IGC), a rapidly growing materials and infrastructure company in India, announ
Read more →IGCIndia Globalization Capital Inc. (IGC) Receives Noncompliance Warning Letter from the Amex BETHESDA, Md.
Globalization Capital Inc. (IGC) Receives Noncompliance Warning Letter from the Md., April 2, 2010 - Marketwire - India Globalization Capital, Inc. (NYSE Amex: IGC), reported that on March 31, 2010 it received a warning letter from the staff of NYSE Amex LLC ("NYSE Amex" or th
Read more →IGCIndia Globalization Capital Commissions First Quarry for Commercial Use, Second Expected to Begin Production in February Two Quarries Represent $40 Million in Potential Revenue over 5-7 Years BETHESDA, Md.
Globalization Capital Commissions First Quarry for Commercial Use, Second Expected to Begin Production in February Quarries Represent $40 Million in Potential Revenue over 5-7 Years Md., Jan. 6, 2010 - MARKETWIRE - India Globalization Capital, Inc. (NYSE Amex: IGC), a company
Read more →IGCIndia Globalization Capital Inc. (IGC) Receives Noncompliance Warning Letter from the Amex BETHESDA, Md., November 13 / PRNewswire-FirstCall/ -- India Globalization Capital, Inc. (NYSE Amex: IGC), (NYSE Amex: IGC-WT), a
Globalization Capital Inc. (IGC) Receives Noncompliance Warning Letter from the Md., November 13 / PRNewswire-FirstCall/ -- India Globalization Capital, Inc. (NYSE Amex: IGC), (NYSE Amex: IGC-WT), a U.S.-based company developing infrastructure in India through its majority-own
Read more →IGCIndia Globalization Capital to Raise about $2 Million in Registered Direct Financing. Bethesda, Md. --(Marketwire-India Globalization Capital (NYSE Amex: IGC), a company developing infrastructure in India, today announce
India Globalization Capital to Raise about $2 Million in Registered Direct Financing. Bethesda, Md. --(Marketwire-India Globalization Capital (NYSE Amex: IGC), a company developing infrastructure in India, today announced that it has received commitments from investors to purcha
Read more →IGCIndia Globalization Capital Inc. (IGC) and its Subsidiaries File Financial Results for Fiscal Year Ended
Globalization Capital Inc. (IGC) and its Subsidiaries File Financial Results for Fiscal Year Ended March 31, 2008 Pro Forma Revenue Up Over 100%; Growth Expected to Accelerate in FYE Md., July 16, 2008 -- (PR NEWSWIRE) -- India Globalization Capital, Inc. (AMEX: IGC.U), (AMEX
Read more →IGCIndia Globalization Capital Amex: IGC Conference presentation, June 2008 www.indiaglobalcap.com Forward-Looking Statements We believe that some of the information in this presentation constitutes forward-looking statemen
Globalization Capital presentation, June 2008 www.indiaglobalcap.com Indian Infrastructure Company Sachs, "Dreaming with BRICs"; "World Bank, April 2008"; Book"; www.childrendatabank.org Confidence on the Rise Spending is a Catalyst for Growth Source: Government of India
Read more →IGCIndia Globalization Capital Amex: IGC Investor presentation, January 2008 3 Forward-Looking Statements We believe that some of the information in this presentation constitutes forward-looking statements within the defini
An escrow value of approximately $5.85 is achieved at a P/E ratio of 6.4x NFYE's earnings. Stock Price Analysis 53 Summary High Growth: India expects to spend $475 billion on infrastructure in the next 4-5 years. Arbitrage: Buying at an escrow price of 6.4 times FYE 3/31/09 proje
Read more →IGCRam Mukunda Chief Executive Officer and President India Globalization Capital, Inc. (301) 983-0998 FOR IMMEDIATE RELEASE INDIA GLOBALIZATION CAPITAL
Chief Executive Officer and President India Globalization Capital, Inc. INDIA GLOBALIZATION CAPITAL, INC. ANNOUNCES CHANGES IN FINANCIAL MANAGEMENT BETHESDA, Maryland, December 1, 2006 India Globalization Capital, Inc. (the Company ) (AMEX: IGC.U) today announced that John C
Read more →IGCRam Mukunda Chief Executive Officer and President India Globalization Capital, Inc. (301) 983-0998 FOR IMMEDIATE RELEASE INDIA GLOBALIZATION CAPITAL, INC. TO RESTATE FINANCIAL STATEMENTS FOR PRIOR FISCAL PERIODS
Chief Executive Officer and President India Globalization Capital, Inc. INDIA GLOBALIZATION CAPITAL, INC. TO RESTATE FINANCIAL STATEMENTS FOR PRIOR FISCAL PERIODS Current Cash Position Not Impacted Maryland, August 18, 2006 India Globalization Capital, Inc. (AMEX: IGC.U) (th
Read more →IGCThe Company has agreed to pay Integrated Global Network, LLC, a related party and privately-held company where one of the Founding Stockholders serves in an executive capacity, an administrative fee of $4,000 per month f
INDIA GLOBALIZATION CAPITAL, INC. (a development stage company) INDEX TO FINANCIAL STATEMENTS Financial Statements Page Report of independent registered public accounting firm 2 Balance sheet as of March 8, 2006 3 Statement of operations for the period from April 29,
Read more →Competitive Position
How IGC ranks across every disease it competes inCompetitive Position is a premium feature
See how IGC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial